Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis

Table 1

Laboratory data on admission.

CBC		Chemistry		Bone marrow
WBC	113,500/μl	LDH	2,162 U/l	NCC	1,30,000/μl
Blasts	83.0%	AST	74 U/l	Megakaryocytes	0.0/μl
Promyelocytes	1.0%	ALT	444 U/l	M/E	11.40
Myelocytes	2.0%	ALP	250 U/l	Blasts	83.8%
Metamyelocytes	2.0%	T-Bil	0.59 mg/dl	Promyelocytes	1.0%
Stabs	0.0%	T-Pro	6.0 g/dl	Myelocytes	1.0%
Segmented	2.0%	Na	139 mEq/l	Metamyelocytes	0.6%
Eosinophils	0.0%	K	4.3 mEq/l	Slabs	1.4%
Basophils	0.0%	Cl	107 mEq/l	Segmented	1.0%
Monocytes	32.0%	BUN	17.9 mg/dl	Eosinophils	0.0%
Lymphocytes	7.0%	Creatinine	1.18 mg/dl	Basophils	0.0%
Reticulocytes	5.5%	CRP	1.2 mg/dl	Monocytes	1.2%
RBC	289 × 10^4/μl	—	—	Lymphocytes	2.0%
Hemoglobin	8.8 g/dl	—	—	G-banding	46,XY,t(9;22)(q34;q11.2)
PLT	2.1 × 10^4/μl	—	—	Major bcr/abl mRNA	1.0 × 10^5 copies/μg RNA

CBC: complete blood cell count, WBC: white blood cells, RBC: red blood cells, PLT: platelets, LDH: lactate dehydrogenase, AST: alanine aminotransferase, ALT: aspartate aminotransferase, ALP: alkaline phosphatase, T-Bil: total bilirubin, T-Pro: total protein, BUN: blood urea nitrogen, CRP: C-reactive protein, NCC: nuclear cell count, and M/E: myeloid to erythroid ratio.